Higher patient adherence to DMDs reduces MS costs
Posted: Wed Nov 30, 2011 12:37 am
Avi Dor, Ph.D., professor in the Department of Health Policy, GW School of Public Health and Health Services, was a co-author of a study, in collaboration with Teva Pharmaceuticals, that found that higher patient adherence to disease modifying therapies, like glatiramer acetate (GA), an immunomodulator drug currently used to treat multiple sclerosis, reduced inpatient costs, outpatient costs, and other medical expenses in a national sample of multiple sclerosis patients.
This research was published in the December issue of the Journal of Medical Economics....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1903